Revenue
2022
2023
2024
2025
Skinbiotherapeutics plc (SBTX)
Price£0.0950Cached quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | £4.6M | £1.2M | £132,057 | £74,761 |
| Research & development | £127,347 | £562,911 | £930,636 | £861,383 |
| Operating expenses | £4.0M | £3.6M | £3.0M | £2.8M |
| Operating income | −£1.1M | −£3.0M | −£3.0M | −£2.7M |
| Operating margin | −24.06% | −244.47% | −2,237.77% | −3,631.57% |
| EBITDA | −£196,540 | −£2.7M | −£2.9M | −£2.9M |
| EBITDA margin | −4.24% | −225.80% | −2,224.33% | −3,935.58% |
| Net income | −£696,253 | −£2.9M | −£2.8M | −£2.8M |
| Net profit margin | −15.01% | −237.95% | −2,146.91% | −3,735.37% |
| Basic EPSper basic share | -£0.00 | -£0.02 | -£0.02 | -£0.02 |
| Diluted EPSper diluted share | -£0.00 | -£0.02 | -£0.02 | -£0.02 |